X
Xiuyi Zhi
Researcher at Capital Medical University
Publications - 77
Citations - 5264
Xiuyi Zhi is an academic researcher from Capital Medical University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 14, co-authored 74 publications receiving 4542 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Jifeng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more
TL;DR: It is suggested that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC, and was associated with more favourable tolerability than standard chemotherapy.
Journal ArticleDOI
Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Ji Feng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jian Wang,Songwen Zhou,Shengxiang Ren,Shaoyong Lu,Lin Zhang,Chengping Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +21 more
TL;DR: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutation-positive advanced non-small-cell lung cancer patients, suggesting that erlotinib should be considered standard first-line treatment of EGfr mutant patients and EGFR -TKI treatment following first- line therapy also brings significant benefits to those patients.
Journal ArticleDOI
Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry.
Wenhua Liang,Jiaxi He,Yaxing Shen,Jianfei Shen,Qihua He,Jianrong Zhang,Gening Jiang,Qun Wang,Lunxu Liu,Shugeng Gao,Deruo Liu,Zheng Wang,Zhihua Zhu,Calvin S.H. Ng,Chia-Chuan Liu,René Horsleben Petersen,Gaetano Rocco,Thomas A. D'Amico,Alessandro Brunelli,Haiquan Chen,Xiuyi Zhi,Bo Liu,Yixin Yang,Wensen Chen,Qian Zhou,Jianxing He +25 more
TL;DR: A greater number of ELNs is associated with more-accurate node staging and better long-term survival of resected NSCLC and is recommended as the cut point for evaluating the quality of LN examination or prognostic stratification postoperatively for patients with declared node-negative disease.
Journal ArticleDOI
Promoter demethylation of WIF-1 by epigallocatechin-3-gallate in lung cancer cells.
Zhi Gao,Zhidong Xu,Ming-Szu Hung,Yu-Ching Lin,Tianyou Wang,Min Gong,Xiuyi Zhi,David M Jablon,Liang You +8 more
TL;DR: The potential therapeutic use of EGCG for the reversal of WIF-1 promoter methylation is suggested and demonstrated in H460 and A549 cell lines.
Journal ArticleDOI
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
Gongyan Chen,Ji Feng Feng,Caicun Zhou,Yi-Long Wu,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jian Wang,Songwen Zhou,Shengxiang Ren,Shaoyong Lu,Lei Zhang,C.-P. Hu,Chengping Hu,Y. Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yuling Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more
TL;DR: Erlotinib improves QoL compared with standard chemotherapy in the first-line treatment of patients with EGFR mutation-positive advanced NSCLC and updated PFS analyses from this study are described.